Novavax, Inc. (NVAX)
Makes vaccines to prevent COVID-19 and malaria
$7.37-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+12.3%
The outlook
Novavax trades near $7.37, well below both its 50- and 200-day moving averages, sitting near the lower end of its 52-week range. Analysts lean bullish with a "buy" consensus, and the average price target sits roughly 91% above the current price, though the stock's overall score remains neutral. The wide gap between current price and targets reflects significant analyst optimism, but near-term momentum remains weak.
What’s behind the score
Analyst consensusBuy — 2.3 avg of 9 analysts
Price trendBelow its 50- & 200-day averages
52-week range20% of the way from its 52-week low to high
Price targetAvg target +91% vs current price
Analyst price target
~12-month · 9 analysts$14.11average target+91.5% vs now
Now $7.37
Low $7.00High $25.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.21B
52-wk high
$11.97
52-wk low
$6.20
50-day avg
$9.12
200-day avg
$8.50
Trailing P/E
—